共 13 条
[1]
Basic principles of platelet biology and clinical implications. Angiolillo DJ,,Ueno M,Goto S. Circulation Journal . 2010
[2]
Routine up-stream versus selective downstream administration of glycoproteinⅡb/Ⅲa inhibitors in patients with non-ST-elevation acute coro-nary syndromes. Sciahbasi A,Biondi-Zoccai G,Romagnoli E,et al. International Journal of Cardiology . 2010
[3]
Effect of CYP2C19 andABCB1 single nucleotide polymorphisms on outcomes of treatmentwith ticagrelor versus clopidogrel for acute coronary syndromes. Wallentin L,James S,Storey RF,et al. The Lancet . 2010
[4]
2011 ACCF/AHA fo-cused update of the guidelines for the management of patients withunstable angina/non-ST-elevation myocardial infarction(updatingthe 2007 guideline). Wright RS,Anderson JL,Adams CD,et al. Journal of the American College of Cardiology . 2011
[5]
Double-dose versusstandard-dose clopidogrel and high-dose versus low-dose aspirin inindividuals undergoing percutaneous coronary intervention for acutecoronary syndromes(CURRENT-OASIS 7). Mehta SR,Tanguay JF,Eikelboom JW,et al. The Lancet . 2010
[6]
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial[J] . Shamir R Mehta,Jean-Francois Tanguay,John W Eikelboom,Sanjit S Jolly,Campbell D Joyner,Christopher B Granger,David P Faxon,Hans-Jurgen Rupprecht,Andrzej Budaj,Alvaro Avezum,Petr Widimsky,Philippe Gabriel Steg,Jean-Pierre Bassand,Gilles Montalescot,Carlos Macaya,Giuseppe Di
[7]
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. Wallentin L,Becker RC,Budaj A,et al. The New England Journal of Medicine . 2009
[8]
Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH 530348 for non-ST-segment elevation acute coronary syndrome. S Goto,T Yamaguchi,Y Ikeda,K Kato,H Yamaguchi,P Jensen. Journal of Atherosclerosis and Thrombosis . 2010
[9]
Safety andtolerability of SCH530348in patients undergoing non-urgentpercutaneous coronary intervention:a randomised,double-blindplacebo-controlled phase II study. Becker RC,Moliterno DJ,Jennings LK,et al. The Lancet . 2009
[10]
Effects of CYP2C19genotype on outcomes of clopidogrel treatment. ParéG,Mehta SR,Yusuf S,Anand SS,Connolly SJ,Hirsh J,Simonsen K,Bhatt DL,Fox KA,Eikelboom JW. The New England Journal of Medicine . 2010